Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Cómo citar

Mariano Provencio, & Ernest Nadal, & Amelia Insa, & María Rosario García-Campelo, & Joaquín Casal‐Rubio, & Manuel Dómine, & Margarita Majem, & Delvys Rodríguez‐Abreu, & Alex Martínez‐Martí, & Javier de Castro, & Manuel Cobo, & Guillermo López-Vivanco, & E. del Barco, & Reyes Bernabé Caro, & Núria Viñolas, & Isidoro Barneto Aranda, & Santiago Viteri, & Eva Pereira, & Ana Royuela, & Marta Casarrubios, & Clara Salas, & Edwin R. Parra, & Ignacio I. Wistuba, & Virginia Calvo, & Raquel Laza‐Briviesca, & Atocha Romero, & Bartomeu Massutí, & Alberto Cruz‐Bermúdez (2020). Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. https://doi.org/10.1016/s1470-2045(20)30453-8